Ryan Beal, M.D. | Tumor Acidity, Drug Delivery, and Therapeutic Innovation
Ryan Beal, M.D., Founder and CEO of Dyve Biosciences, joins Executive Insights for Life Sciences Innovators to discuss translating established biology into new therapeutic approaches. The conversation explores the role of tumor acidity in immune suppression and treatment response, Dyve’s transdermal delivery platform and its application to pH modulation, and the leadership decisions involved in advancing an unconventional therapeutic hypothesis toward the clinic.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Ryan Beal discusses how tumor acidity may influence immune suppression and treatment response, and how Dyve Biosciences is applying its transdermal delivery platform to pH modulation. The conversation also explores the company’s collaboration with Moffitt Cancer Center, the challenges of translating established biological insights into practical therapies, and the leadership decisions involved in moving an unconventional therapeutic approach toward clinical development.
Key Themes
- The role of tumor acidity in immune suppression and treatment response
- Translating established biology into new therapeutic approaches
- Dyve Biosciences’ transdermal delivery platform and pH modulation
- The challenges of advancing unconventional therapeutic hypotheses toward the clinic
- Collaboration with Moffitt Cancer Center
- Leadership and company-building decisions in early-stage therapeutic development
Why This Matters for Life Sciences Leaders
Scientific understanding does not always translate easily into practical therapies. For biotech founders and life sciences leaders, the challenge is identifying where established biology presents an opportunity, developing a viable path toward clinical application, and making disciplined decisions amid scientific and commercial uncertainty. Ryan Beal’s experience offers a perspective on the leadership, collaboration, and execution required to move an unconventional therapeutic approach from hypothesis toward clinical development.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.






